Phase 2 N=30 CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas
Non-Hodgkin Lymphoma · Mycosis Fungoides
Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=18 Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
EBV-Related Post-Transplant Lymphoproliferative Disorder · Monomorphic Post-Transplant Lymphoproliferative Disorder · Polymorphic Post-Transplant Lymphoproliferative Disorder
Primary: Percentage of Patients Assigned to Arm Latent Membrane Protein-specific T-cells (LMP-TC) With Successful LMP-specific T Cell Product Match, Were Treated Within Two Weeks…
Phase 2 N=1 Leflunomide for the Treatment of Relapsed or Refractory CD30+ Lymphoproliferative Disorders
Recurrent Lymphoproliferative Disorder · Refractory Lymphoproliferative Disorder
Primary: Overall Response Rate — 0 percentage of participants
Phase 3 N=503 Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Lymphoma, Non-Hodgkin
Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296
N/A N=39 Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant
Leukemia · Lymphoma · Multiple Myeloma and Plasma Cell Neoplasm
Primary: Complete Remission Rate — 8; 6 Participants
Phase 1 N=40 LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
Hodgkin Disease · Non Hodgkin Lymphoma · Lymphoepithelioma
Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…
Phase 2 N=35 Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Diffuse Large B Cell Lymphoma Relapsed · Diffuse Large B Cell Lymphoma Refractory
Primary: Number of Participants With Dose-Limiting Toxicities as a Measure of Safety and Tolerability — 0; 0; 0; 1 Participants
Phase 2 N=55 Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation
Lymphoproliferative Disorder
Primary: Event-free Survival — 71 percentage of participants analyzed
Phase 2 N=42 Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia · Recurrent Childhood B-Lymphoblastic Lymphoma
Primary: 3-year Overall Survival Rate of Patients With Relapsed ALL — 94.4; 55.5; 72.63 percentage of participants — p=0.035
N/A N=1,598 B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and Outcomes
Classical Hodgkin Lymphoma · Relapsed or Refractory Classical Hodgkin Lymphoma
Primary: Group 2, RRHL: Progression Free Survival (PFS) — 13.17 months
Phase 2 N=7 Bortezomib Plus Rituximab for EBV+ PTLD
Post-transplant Lymphoproliferative Disease · Solid Organ Transplant · Stem Cell Transplant (Bone Marrow Transplant)
Primary: Overall Response Rate — 3 Participants
N/A N=158 Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma
Diffuse Large B-cell Lymphoma
Primary: R-IPI Index (Revised International Prognostic Index) — 3.4; 32.2; 64.4 percentage of participants
Phase 2 N=35 Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma · Diffuse Large Cell Lymphoma · Mantle Cell Lymphoma
Primary: Event-free Survival (EFS) — 83 percentage of not experiencing EFS event
Phase 2 N=38 A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Primary: Percentage of Participants With a Complete Remission (CR) or Partial Remission (PR) — 39.5 percentage of participants
N/A N=8 Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation
Leukemia, Myeloid, Acute · Leukemia, Lymphoblastic, Acute · Leukemia, Myelocytic, Chronic
Primary: Overall Recipient Survival at 6-month Post-relapse of Disease — 0; 4 participants
Phase 3 N=358 Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
Lymphoma, Non-Hodgkin
Primary: Kaplan Meier Estimate of Progression Free Survival Assessed by the Independent Review Committee (IRC) According to the 2007 International Working Group Response Criteria…
Phase 2 N=43 Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Non-Hodgkins Lymphoma
Primary: Percentage of Participants With Response — 23.3 percentage of participants
Phase 2 N=134 Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Relapsed Diffuse Large B-Cell Lymphoma · Refractory Diffuse Large B-Cell Lymphoma
Primary: Phase 1b: Recommended Phase 2 Dose of Lenalidomide in Combination With Fixed Doses of Ibrutinib and Rituximab in Participants With Relapsed or Refractory Diffuse Large B…
Phase 2 N=8 Maintenance Lenalidomide in Lymphoma
Lymphoma
Primary: Number of Subjects With Dose-limiting Toxicities — 0 Participants
N/A N=26 Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT
Hodgkin's Disease · Leukemia · Myelodysplastic Syndrome
Primary: Safety of Rituximab Prophylaxis — 23 participants
Phase 2 N=103 Bortezomib in Treating Patients With Lymphoproliferative Disorders
Recurrent Grade 1 Follicular Lymphoma · Recurrent Grade 2 Follicular Lymphoma · Recurrent Grade 3 Follicular Lymphoma
Primary: Response Rate — 11; 6 participants
Phase 2 N=48 Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma
Diffuse Large B-cell Lymphoma
Primary: 1-year Progression-free Survival — 31 Participants
Phase 2 N=64 Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Relapsed or Refractory Follicular Lymphoma
Follicular Lymphoma
Primary: Progression-free Survival — 59 percent chance of PFS at 5 years
Phase 2 N=23 Autologous and Allogeneic Transplant for Relapsed Lymphoma
Non-Hodgkin's Lymphoma · Hodgkins Disease
Primary: Total Number of Subjects With a Complete Response (CR) Following Myeloablative Conditioning (MAC) and Autologous Stem Cell Transplantation (AutoSCT) — 4; 12 Participants
Phase 2 N=55 A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.
Non-Hodgkin's Lymphoma
Primary: Percentage of Participants With Relapsed or Refractory DLBCL Who Are Progression-Free for at Least 2 Cycles (28-Day Cycles) After Receiving Enzastaurin (LY317615)…
Phase 2 N=48 Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue
Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
Primary: Objective Responses in Patients With MALT Lymphoma Presenting With Measureable Disease — 25; 20; 1 Participants
Phase 2 N=72 CT-011 MAb in DLBCL Patients Following ASCT
Lymphoma, Large Cell, Diffuse · Lymphoma, Mixed Cell, Diffuse · Primary Mediastinal Large B-Cell Lymphoma
Primary: Progression-free Survival — 72 Percent
Phase 2 N=50 Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
Follicular Lymphoma · Marginal Zone B-Cell Lymphoma · MALT Lymphoma
Primary: Response Rate to Lenalidomide-dexamethasone + Rituximab Therapy in Relapsed Small B-cell Lymphoma With Rituximab Resistance — 14; 13 Participants
Phase 2 N=17 LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma
Non-Hodgkin's Lymphoma
Primary: Complete Remission — 10 participants
Phase 2 N=30 Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia · CLL
Primary: Overall Response Rate (ORR) — 25 Participants